| Literature DB >> 32397375 |
Elena Khashchenko1, Mikhail Vysokikh2,3, Elena Uvarova1, Lyubov Krechetova4, Valentina Vtorushina4, Tatyana Ivanets5, Maria Volodina2,6, Nadezhda Tarasova2,7, Iuliia Sukhanova2, Gennady Sukhikh8.
Abstract
RELEVANCE: Mitochondrial dysfunction and systemic inflammation are believed to play pivotal role in the pathogenesis of polycystic ovary syndrome (PCOS) and related complications of metabolic disorders in adult patients. Though such researches are limited or almost absent in adolescents. The aim of the study is to evaluate the impact of mitochondrial dysfunction and systemic inflammation on PCOS pathogenesis during adolescence with regard to body mass index and insulin resistance.Entities:
Keywords: C-reactive protein; apoptosis; insulin resistance; interleukins; lipid peroxidation; malondialdehyde; mitochondrial dysfunction; polycystic ovary syndrome; systemic inflammation
Year: 2020 PMID: 32397375 PMCID: PMC7291245 DOI: 10.3390/jcm9051399
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Blood lipid profile values, results of the oral glucose tolerance test (OGTT) and visceral adiposity index (VAI) values in adolescents with polycystic ovary syndrome (PCOS), grouped by BMI and presence of MD.
| Values | Groups of PCOS Patients ( | Сontrol Group ( | ||||
|---|---|---|---|---|---|---|
| MD−/NW ( | МD−/OW ( | МD+/NW ( | МD+/OW ( | |||
| Cholesterol **, mmol/L | 4.2 (3.9–5.1) | 4.4 (4.0–5.1) | 4.9 (4.5–5.2) | 4.0 (3.7–4.9) | 4.1 (3.5–4.8) | 0.4879 |
| TG *, mmol/L | 0.7 ± 0.2 | 0.9 ± 0.5 | 1.1 ± 0.5 | 1.2 ± 0.5 | 0.8 ± 0.6 | 0.0001 |
| HDL *, mmol/L | 1.6 ± 0.4 | 1.5 ± 0.2 | 1.4 ± 0.6 | 1.4 ± 0.5 | 1.7 ± 0.4 | 0.0180 |
| LDL *, mmol/L | 2.1 ± 0.7 | 2.2 ± 0.5 | 2.6 ± 0.7 | 2.4 ± 0.8 | 2.0 ± 0.7 | 0.1802 |
| Atherogenic index * | 1.8 ± 0.6 | 2.1 ± 0.4 | 2.6 ± 0.7 | 2.8 ± 1.3 | 1.7 ± 0.7 | 0.0046 |
| Glucose 0’ *, mmol/L | 5.0 ± 0.4 | 4.9 ± 0.4 | 5.2 ± 0.5 | 5.2 ± 0.5 | 4.9 ± 0.4 | 0.0626 |
| Glucose 120’ *, mmol/L | 5.3 ± 0.9 | 5.9 ± 0.6 | 6.6 ± 1.3 | 7.9 ± 3.7 | - | 0.0009 |
| Insulin 0’ *, mIU/mL | 9.7 ± 3.1 | 12.4 ± 4.0 | 16.3 ± 9.0 | 30.1 ± 26.6 | 10.5 ± 3.3 | 0.0000 |
| Insulin 120’ **, mIU/mL | 20.0 (7.4–29.3) | 17.0 (8.4–20.7) | 22.0 (15.0–40.9) | 59.2 (37.7–129.2) | - | 0.0000 |
| НОМА-IR ** | 1.9 (1.5–2.8) | 2.9 (1.9–3.4) | 3.6 (2.0–4.4) | 5.4 (3.8–7.6) | 2.2 (1.9–2.5) | 0.0000 |
| VAI ** | 0.6 (0.5–1.0) | 0.9 (0.6–1.7) | 1.0 (0.8–1.6) | 1.6 (1.1–2.0) | 0.6 (0.4–1.0) | 0.0013 |
* variable with a normal distribution, data are presented as mean ± standard deviation, ANOVA test (LSD test and Newman–Keuls test for intergroup comparisons); ** variable with a non-normal distribution, data are presented as median, 25–75 percentiles (Kruskal–Wallis test and Dunn test for intergroup comparisons).
The level of CRP and leptin in peripheral blood in adolescent girls with PCOS, grouped by BMI and presence of MD.
| Parameters | Groups of PCOS Patients ( | Control Group ( | ||||
|---|---|---|---|---|---|---|
| MD−/NW ( | MD−/OW ( | MD +/NW ( | MD +/OW ( | |||
| CRP *, mg/L | 0.7 ± 0.7 | 1.8 ± 1.8 | 0.8 ± 1.2 | 2.2 ± 2.4 | 1.0 ± 0.9 | 0.0412 |
| Leptin **, ng/mL | 17.4 (8.9–24.6) | 51.7 (23.7–65.7) | 35.2 (29.2–43.4) | 50.7 (43.6–63.4) | 19.9 (12.4–28.5) | <0.0001 |
* variable with a normal distribution, data are presented as mean ± standard deviation, ANOVA test (LSD test and Newman–Keuls test for intergroup comparisons); ** variable with a non-normal distribution, data are presented as median, 25–75 percentiles (Kruskal-Wallis test and Dunn test for intergroup comparisons).
Cytokine profile of peripheral blood in adolescent girls with PCOS, grouped by BMI and presence of MD.
| Cytokines | Groups of PCOS Patients ( | Control Group ( | ||||
|---|---|---|---|---|---|---|
| MD−/NW ( | MD−/OW ( | MD +/NW ( | MD + /OW ( | |||
| IL-6 **, pg/mL | 0.06 | 0.30 | 0.06 | 0.62 | 0.39 | 0.5390 |
| IL-10 *, pg/mL | 1.03 ± 0.68 | 0.76 ± 0.63 | 0.78 ± 0.36 | 0.91 ± 0.45 | 0.62 ± 0.35 | 0.5180 |
| IL-18 *, pg/mL | 80.54 ± 80.23 | 65.55 ± 65.82 | 78.26 ± 49.57 | 158.15 ± 138.00 | 68.54 ± 63.08 | 0.0407 |
| TNFα **, pg/mL | 8.72 | 7.78 | 7.07 | 8.74 | 7.91 | 0.7308 |
| MIF *, ng/mL | 1.26 ± 0.74 | 1.29 ± 0.70 | 1.31 ± 1.06 | 2.61 ± 3.11 | 1.84 ± 2.51 | 0.2988 |
| sFas **, ng/mL | 2.20 | 2.59 | 2.17 | 2.30 | 1.98 | 0.6564 |
| sFasL *, pg/mL | 2.48 ± 1.45 | 1.07 ± 0.64 | 1.71 ± 1.29 | 1.89 ± 1.16 | 2.88 ± 1.67 | 0.0694 |
| sFas/sFasL *, pg/mL | 3046.0 ± 4792.4 | 1549.9 ± 760.1 | 2719.0 ± 3202.6 | 2070.1 ± 2656.0 | 1163.5 ± 759.6 | 0.1465 |
* variable with a normal distribution, data are presented as mean ± standard deviation, ANOVA test (LSD test for cross-group comparisons); ** variable with a non-normal distribution, data are presented as median, 25–75 percentile, Kruskal–Wallis test (Dunn’s criterion for intergroup comparisons).
Malondialdehyde (MDA) level in peripheral blood in adolescent girls with PCOS, grouped by BMI and metabolic disorders.
| Parameter | Groups of PCOS Patients ( | Control Group ( | ||||
|---|---|---|---|---|---|---|
| МD−/NW ( | МD−/OW ( | МD+/NW ( | МD+/OW ( | |||
| Plasma MDA*, μМ | 4.44 ± 1.07 | 4.99 ± 0.88 | 4.13 ± 0.85 | 5.40 ± 1.01 | 4.98 ± 0.66 | 0.0005 |
* data are presented as mean ± standard deviation, ANOVA test (LSD test for intergroup comparisons).
Figure 1Two-factor analysis of variance of the interaction between BMI and metabolic disorders (MD) on the MDA level in adolescent girls with PCOS (LS means, vertical bars denote 0.55 confidence intervals).